# Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

> **NCT00066625** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** oxaliplatin
- **DRUG:** bortezomib
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00066625
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-07
- **Primary completion:** 2007-04
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066625, "Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00066625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*